Treating Psoriasis Patients With Biologic Agents

Improved outcomes with new biologic agents are prompting physicians to integrate them into therapy for psoriasis patients.

David M. Pariser, MD
Professor, Department of Dermatology, Eastern Virginia Medical School, Norfolk, Va.

The advent of biologic response modifiers for the treatment of psoriasis is bringing a dramatic shift in the way that dermatologists provide care for patients with this major chronic disease, which currently affects more than 4.5 million American adults (National Psoriasis Foundation [NPF] 2003).

Limited experience with these specialty drugs and their unique delivery methods have given rise to reluctance among some dermatologists to utilize these agents in the care of psoriasis patients. Yet the extremely positive results that we as dermatologists see increasingly in our patients who are receiving these novel drugs make it incumbent on us to establish their place in our practice.

Plaque psoriasis is a painful and disfiguring condition that has severe adverse effects. These negative effects extend to patient quality of life, as well as work, family, finances, social life, leisure activities, sexual relations, and physical and emotional well-being.

Includes commentary by Jeffrey Lenow, MD, JD, Associate Professor, Jefferson Medical College of Thomas Jefferson University

Author correspondence:
David M. Pariser, MD
Professor, Department of Dermatology
Eastern Virginia Medical School
601 Medical Tower
Norfolk, VA 23507

A blueprint for high-volume, high-quality lung cancer screening that is detecting cancer earlier—and helping to save lives

Clinical Brief

Multiple Sclerosis: New Perspectives on the Patient Journey–2019 Update
Summary of an Actuarial Analysis and Report